CLEVELAND, OH — Two studies conducted by the Cleveland Clinic revealed how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies. The studies, published in the October 12 issue of JAMA Oncology, suggest that men who inherit this variant would benefit from a personalized…...
Firefighters: Heroes in the Line of Fire
All consuming, unforgiving, destructive: adjectives easily attributable to the symptoms, treatments, diagnosis and battle with cancer. These descriptors also paint an accurate rendering of the infernos into which American fire fighters, America’s Bravest, venture unflinchingly as they perform their duty. In a recent exposé, experts uncovered a disturbing trend which…...
Novel CAR-T Treatment Approved for Second Indication
In the past two months, the FDA has approved a revolutionary new form of immunotherapy, called chimeric antigen receptor (CAR) T cell therapy, for two blood cancers: B cell acute lymphoblastic leukemia (ALL) in August, 2017 and now on October 18th, for aggressive diffuse large B cell lymphoma (DLBCL), a…...
NFCR President and COO to co-organize and speak at SNOChina 2018
The Society for Neuro-Oncology of China has invited Dr. Sujuan Ba, the president and chief operating officer of the National Foundation for Cancer Research (NFCR), to give a lecture at its annual meeting, SNOChina 2018, to be held in Changsha, Hunan on March 16-17, 2018. The Society will present the…...
Infectious Disease Agents as a Cause of Cancer
Cancer is a group of diseases defined by abnormal cell growth and caused by genetic defects. Most of us know that these genetic defects can be inherited, caused by environmental factors such as smoking, drinking, obesity and a lack of physical activity, as well as exposure to radiation and pollution.…...
Triple Negative Breast Cancer – What Every Patient Should Know
Nearly 15-20% of breast cancers are so-called “triple negative,” meaning such cancers have tested negative in pathology reports for estrogen receptors, progesterone receptors, and Her2/Neu. The growth of these cancers are not fueled by estrogen and progesterone, as are most cancers, and therefore, do not respond to hormonal therapies such as…...
Strategic Media Partner
